@article {Tang161作者={唐,Shenjie和姚明、局域网和郝晓惠张,夏和刘,帮派和刘,鑫和吴,Meiying禅,临海和太阳,华和刘,Yidian顾,金和林,Feishen王,Xiafang张,展君},title ={有效性、安全性和耐受性的linezolid广泛耐药结核的治疗:a study in China}， volume = {45}， number = {1}， pages ={161—170}，year = {2015}， doi = {10.1183/09031936.00035114}， publisher = {Eur188bet官网地址opean Respiratory Society}， abstract ={利奈唑胺可能对多药耐药肺结核和广谱耐药肺结核有效。我们进行了一项前瞻性、多中心、随机研究，以进一步评估疗效，将65例广谱耐药肺结核痰培养阳性患者随机分为利奈唑胺治疗组和对照组。两组患者均采用2年个体化化疗方案。利奈唑胺治疗组给予利奈唑胺开始剂量为1200毫克/天，持续4周6周，随后给予300毫克/天。利奈唑胺治疗组24个月时痰培养转化率为78.8\%，显著高于对照组(37.6\%，p\<0.001)。利奈唑胺治疗组治疗成功率为69.7%，显著高于对照组(34.4%，p=0.004)。利奈唑胺组27例(81.8%)患者发生了临床显著不良事件，其中25例(93 %)患者发生了可能或可能与利奈唑胺有关的事件。大多数不良事件在减少利奈唑胺剂量或暂时停用利奈唑胺后得到解决。 Linezolid containing chemotherapy for treatment of extensively drug-resistant tuberculosis may significantly promote cavity closure, increase sputum culture-conversion rate and improve treatment success rate. Prospective, multicentre, randomised study evaluating efficacy, safety and tolerability of linezolid in XDR-TB http://ow.ly/ztVfd}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/45/1/161}, eprint = {//www.qdcxjkg.com/content/45/1/161.full.pdf}, journal = {European Respiratory Journal} }